World Model · podcast knowledge graph

Machine Learning: A New Approach to Drug Discovery with Daphne Koller - #332

2019-12-26 · 43 min · episode 332 · 16 entities

episode page audio

Asserted relationships

Entities found in this episode

companys 7

  • mentioned TWIML company
    0.70
    evidence rules-v4
    Feed author/publisher: TWIML
  • 0.62
    evidence rules-v4
    CEO of Coursera and Founder and CEO of
  • mentioned Technology company
    0.50
    evidence rules-v4
    Feed category: Technology
  • 0.50
    evidence rules-v4
    CEO of Coursera and Founder and CEO of
  • 0.50
    evidence rules-v4
    CEO of Coursera and Founder and CEO of
  • discusses Technology company
    0.40
    evidence rules-v4
    Feed category: Technology
  • hosted by TWIML company
    0.40
    evidence rules-v4
    Feed author/publisher: TWIML

concepts 5

  • mentioned Science concept
    0.50
    evidence rules-v4
    Feed category: Science
  • mentioned Tech News concept
    0.50
    evidence rules-v4
    Feed category: Tech News
  • discusses Science concept
    0.40
    evidence rules-v4
    Feed category: Science
  • discusses News concept
    0.40
    evidence rules-v4
    Feed category: News
  • discusses Tech News concept
    0.40
    evidence rules-v4
    Feed category: Tech News

persons 3

  • mentioned Daphne Koller person
    0.72
    evidence rules-v4
    Machine Learning: A New Approach to Drug Discovery with Daphne Koller - #332
  • mentioned Sam Charrington person
    0.70
    evidence rules-v4
    Feed author/publisher: Sam Charrington
  • hosted by Sam Charrington person
    0.55
    evidence rules-v4
    Feed author/publisher: Sam Charrington

podcasts 1

Episode description as stored
Today we’re joined by Daphne Koller, co-Founder and former co-CEO of Coursera and Founder and CEO of Insitro. In our conversation, discuss the current landscape of pharmaceutical drugs and drug discovery, including the current pricing of drugs, and an overview of Insitro’s goal of using ML as a “compass” in drug discovery. We also explore how Insitro functions as a company, their focus on the biology of drug discovery and the landscape of ML techniques being used, Daphne’s thoughts on AutoML, and